Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain

This study has been completed.
Sponsor:
Information provided by:
AcelRx Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00833040
First received: January 28, 2009
Last updated: April 5, 2010
Last verified: April 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)